Kodiak Sciences (KOD) Cash & Equivalents (2017 - 2026)

Kodiak Sciences' Cash & Equivalents history runs 10 years deep, the most recent figure standing at $169.5 million for Q1 2026.

• Quarterly Cash & Equivalents rose 22.09% year-over-year to $169.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $169.5 million (up 22.09% YoY) and the FY2025 annual result came in at $209.9 million, up 24.86% from the prior year.
• Cash & Equivalents was $169.5 million for Q1 2026 at Kodiak Sciences, down from $209.9 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $671.7 million in Q1 2022 and bottomed at $72.0 million in Q3 2025.
• A 5-year average of $239.5 million and a median of $197.9 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 80.4% — and 2023, when it soared 119.27%.
• Kodiak Sciences' Cash & Equivalents stood at $196.8 million in 2022, then surged by 45.11% to $285.5 million in 2023, then tumbled by 41.13% to $168.1 million in 2024, then increased by 24.86% to $209.9 million in 2025, then declined by 19.22% to $169.5 million in 2026.
• Business Quant data shows KOD's Cash & Equivalents at $169.5 million in Q1 2026, $209.9 million in Q4 2025, and $72.0 million in Q3 2025.